Results 31 to 40 of about 8,600 (158)

Osteoporosis and Periodontitis: Two‐Way Epidemiological and Mechanistic Evidence

Journal of Periodontal Research, EarlyView.
This review investigates the main mechanistic pathways connecting local periodontitis to systemic osteoporosis. Seven interconnected mechanisms are identified. ABSTRACT Osteoporosis and periodontitis are highly prevalent, chronic inflammatory diseases that constitute a major global health burden.
Jia Chang, Geeta Madhuri Bhuvanagiri, Megan Dulkanchainun, Cunyu Wang   +3 more
wiley   +1 more source

An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis

Indian Journal of Endocrinology and Metabolism, 2015
Background: One year, prospective, observational study in an Indian subpopulation to assess back pain in patients with severe osteoporosis treated with teriparatide or antiresorptives in a clinical setting. Materials and Methods: One hundred and nineteen
Harvinder Chhabra, Rajesh Malhotra, Sunil Marwah, Bharat Dave, Kyoungah See, Simrat Sohal, Sirel Gurbuz   +6 more
doaj   +1 more source

Effect of Teriparatide on Bone Mineral Density and Trabecular Bone Score in Type 2 Diabetic Patients with Osteoporosis: A Retrospective Cohort Study

Medicina, 2022
The BMDs of the lumbar spine, whole femur, and femoral neck and TBS were measured. Change in BMD or TBS was defined as the BMD or TBS at follow-up, performed 1 year after baseline, minus baseline BMD or TBS.
Chihiro Munekawa, Yoshitaka Hashimoto, Noriyuki Kitagawa, Takafumi Osaka, Masahide Hamaguchi, Michiaki Fukui   +5 more
doaj   +1 more source

Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw

Oral Diseases, EarlyView.
ABSTRACT Objective This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro.
Hae‐Seo Park, Shihyun Kim, Seo‐Yeong An, Reuben H. Kim, Jongho Choi, Moon‐Young Kim   +5 more
wiley   +1 more source

Acute development of cortical porosity and endosteal naïve bone formation from the daily but not weekly short-term administration of PTH in rabbit. [PDF]

PLoS ONE, 2017
Teriparatide [human parathyroid hormone (1-34)], which exerts an anabolic effect on bone, is used for the treatment of osteoporosis in patients who are at a high risk for fracture.
Hiroshi Yamane, Aya Takakura, Yukari Shimadzu, Toshiyuki Kodama, Ji-Won Lee, Yukihiro Isogai, Toshinori Ishizuya, Ryoko Takao-Kawabata, Tadahiro Iimura   +8 more
doaj   +1 more source

Oral Delivery of Bioencapsulated CTB‐Pro‐IGF‐1 Enhances Bone Regeneration in a Pre‐Clinical Rat Model of Jaw Osteoradionecrosis

Oral Diseases, EarlyView.
ABSTRACT Objective Head and neck cancer radiotherapy can lead to jaw osteoradionecrosis (ORN). There is currently no definitive treatment for ORN. The efficacy of a novel orally delivered aglycosylated IGF‐1 with an E‐peptide (CTB‐Pro‐IGF‐1), bioencapsulated in plant cells, was evaluated as therapy for jaw ORN in rats. Materials and Methods Rat jaw ORN
Sunday O. Akintoye, Arularasan Anbinselvam, Prasath Jeyaraman, Uddhab Karki, Geetanjali Wakade, Henry Daniell   +5 more
wiley   +1 more source

Treatment Trade‐Offs and Choices for Femoral Fractures: A Systematic Review and Meta‐Analysis

Orthopaedic Surgery, Volume 17, Issue 5, Page 1298-1313, May 2025.
This review examines the trade‐offs between surgical intervention and traction therapy for adult and elderly patients with femoral fractures and surgical contraindications, particularly in resource‐limited settings. While intramedullary nailing may offer better clinical outcomes, traction therapy is often preferred due to limited surgical resources ...
Jiarui Li, Zhu Guo, Tianrui Wang, Kunyue Xing, Wenzhuo Wang, Yaowei Liu, Jiyao Xing, Hongfei Xiang, Jingdong Wang, Bohua Chen, Dongming Xing, Xiaolin Wu   +11 more
wiley   +1 more source

First Generic Teriparatide: Structural and Biological Sameness to Its Reference Medicinal Product

Pharmaceutics
Teriparatide is an anabolic peptide drug indicated for the treatment of osteoporosis. Recombinant teriparatide was first approved in 2002 and has since been followed by patent-free alternatives under biosimilar or hybrid regulatory application.
Jimena Fernández-Carneado, Mariona Vallès-Miret, Sílvia Arrastia-Casado, Ana Almazán-Moga, Maria J. Macias, Pau Martin-Malpartida, Marta Vilaseca, Mireia Díaz-Lobo, Mayte Vazquez, Rosa M. Sanahuja, Gemma Gambús, Berta Ponsati   +11 more
doaj   +1 more source

Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.

PLoS ONE, 2020
BackgroundGiving patients anti-osteoporotic agents peri-operatively is a well-accepted strategy to increase fusion rate and prevent complications. The purpose of this study was to investigate effectiveness of teriparatide and bisphosphonate on fusion ...
Shih-Hao Cheng, Yi-Jie Kuo, Chiehfeng Chen, Yi-No Kang   +3 more
doaj   +1 more source

Breaking the Debilitating Cycle: Pathophysiology, Assessment, and Multimodal Intervention of Secondary Debilitation After Hip Fracture in Older Adults—A Narrative Review

Orthopaedic Surgery, EarlyView.
This article provides a comprehensive overview of the pathophysiological mechanisms underlying “secondary debilitation after hip fracture,” discusses the clinical application of risk assessment tools, and presents a phased, stepwise intervention strategy aimed at interrupting the “vicious cycle.” ABSTRACT Hip fractures pose a serious threat to the ...
Wenyang Xu, Fan Xu, Maoqiang Fan, Yao Liu, Zhe Song   +4 more
wiley   +1 more source